{"id":384748,"date":"2020-11-19T06:48:07","date_gmt":"2020-11-19T11:48:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384748"},"modified":"2020-11-19T06:48:07","modified_gmt":"2020-11-19T11:48:07","slug":"apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/","title":{"rendered":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS<\/li>\n<\/ul>\n<p>WALTHAM, Mass. and STOCKHOLM, Sweden, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_LBABDmK9vCjCL3kFhSyAxuXC7FDUXNmUPJLGxg9b-RIBmVqcQWmoGKePFfveMrc83omKRD7FI5AP9PDsePTSp3quEJSQ59G0uERnHDVACc=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Apellis Pharmaceuticals, Inc.<\/a> (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi\u2122) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS).<\/p>\n<p>Studies suggest that elevated levels of C3 may play a role in the progression of ALS, a neurodegenerative disease that leads to progressive muscle weakness and paralysis. The MERIDIAN study will assess whether pegcetacoplan may offer a new treatment approach for people living with ALS by controlling complement activation at the level of C3. There are currently no treatments to slow the advance of ALS.<\/p>\n<p>\u201cALS patients have a very high unmet need. They expect more and better treatment options,\u201d said Bashar Al-Nakhala, chief operations officer of the ALS Therapeutic Development Institute. \u201cWe are pleased that Apellis and Sobi have joined the ALS clinical development community with our shared goal of halting the devastating progression of ALS.\u201d<\/p>\n<p>\u201cBased on the suspected role of C3 in ALS, we are working urgently to understand whether pegcetacoplan, a targeted C3 therapy, has the potential to slow disease progression and make a difference for the ALS community,\u201d said Federico Grossi, M.D., Ph.D, chief medical officer of Apellis. \u201cWe designed the MERIDIAN study based on significant feedback from the community, and we are dedicated to continuing our partnership to one day bring a meaningful therapy to families living with ALS.\u201d<\/p>\n<p>\u201cWe are delighted that the first patient in the Phase 2 clinical study has been dosed as there is an urgency for a treatment for patients with ALS,&#8221; said Ravi Rao, head of R&amp;D and chief medical officer at Sobi. &#8220;In collaboration with Apellis, we look forward to evaluating the potential of pegcetacoplan in patients with ALS.\u201d<\/p>\n<p>The Phase 2 MERIDIAN study (APL2-ALS-206) is a potentially registrational, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of pegcetacoplan in approximately 200 adults with sporadic ALS. Study participants will be randomized in a 2:1 ratio to receive pegcetacoplan or placebo while continuing to receive their existing standard of care treatment for ALS. After 52 weeks of blinded treatment, all patients in the study will receive pegcetacoplan. To reduce the burden on people living with ALS and their caregivers, the study has been designed to minimize the number of in-clinic visits, with approximately six clinic visits in the first year and four in the open-label second year.<\/p>\n<p>The primary endpoint of the study is the Combined Assessment of Function and Survival (CAFS) rank scores at week 52. Key secondary endpoints include measures of lung function, muscle strength, and quality of life. For more information about the Phase 2 MERIDIAN study, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6v1V_kqIQFzkXlYo4BYxuo90532xN1103mBR0GpeQfD33zrul8LpI9mxjXUj8kzPXHI7RJeCptIdEIXlLlYwS1GYREgeF7blGgNVL25-B9dlboyyoYVpsltS9Dtgw7Bq\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.clinicaltrials.gov<\/a> (NCT04579666).<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>Amyotrophic Lateral Sclerosis <\/strong><br \/>\n        <strong>(ALS)<\/strong><br \/>\n        <br \/>ALS is a devastating neurodegenerative disease that results in progressive muscle weakness and paralysis due to the death of nerve cells, called motor neurons, in the brain and spinal cord.<sup>1,2 <\/sup>The death of motor neurons leads to the progressive loss of voluntary muscle movement required for speaking, walking, swallowing, and breathing.<sup>1,2<\/sup> In individuals with ALS, high levels of C3 are present at the neuromuscular junction<sup>3<\/sup> where motor neurons communicate directly to muscle cells. Numerous studies suggest that elevated levels of C3 present throughout the motor system of ALS patients are likely to contribute to chronic neuroinflammation and the death of motor neurons.<sup>3,4,5<\/sup> There are currently no approved treatments that stop or reverse the progression of ALS, which impacts ~225,000 patients worldwide.<sup>6<\/sup><\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>Pegcetacoplan <\/strong><br \/>\n        <strong>(APL-2) <\/strong><br \/>\n        <br \/>Pegcetacoplan is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body\u2019s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan\u00a0is a synthetic cyclic peptide conjugated to a polyethylene glycol polymer that binds specifically to C3 and C3b. Marketing applications for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) are under review by the U.S. Food and Drug Administration (FDA), which has granted the application Priority Review designation, and the European Medicines Agency (EMA). Pegcetacoplan\u00a0was also granted Fast Track designation by the FDA for\u00a0the treatment of PNH and for the treatment of geographic atrophy and received orphan drug designation for the treatment of C3 glomerulopathy by the FDA and EMA. For additional information regarding pegcetacoplan clinical trials,\u00a0visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6v1V_kqIQFzkXlYo4BYxui9rlYYKGSHA-PsOFcPE1b0V-IRpgdoU4ilcra0E7u3RCX9inpnaFlsdJ9-XrW7nqCvsUct--9J5NEIu4tKh518lUHzEEZNVbcCJRl8Qfspc_QBf990mqJWd9dSNYJPYnJUW9EXugz2DpTvSYxdeHUxg7KF4YwT5c9V96b_NKsl96f72FQtd0uqhvjfqIrqtPM6tX8smVMEccC3CqQeMADA3UuGUB4qcudyzrgL0YIdY7gNz7UrA8o6d75ysb9rvTQ0BZjNLS5iZkcUq_1dDM878Pb4ndGFWDBgZfplz4DnnORnPF-a4jQTmV4eeK5ZDdby28bdrLZyCMovOm7nFCtAfFe_kWL8O_nspLEzVmpGCMYjwFQWoSVWlSkxw-QqelJMq6dbpgpmPqhL_irGKFjS4HUrk9LAY__SMAuyqW1OGYZOJ6qYl2wXMjAthnAJO0EuXsCk7rBEEj8z2W89P5hPI2-J4rYkvF7A4_dQPn8gMhDjoFL56ZCFI08wyttI15S2IQchmiIWZ38PqCQ_503NVSBmdGBiWDmAXmUoE01eXbbDNFzHfItZzTa8GoZ_M59a3lMct2FZyhrz4jcXizQpnlUkECAe4qHGMxtg2aFqZ9vmYHVNsV0Y05APYvE95Y56LACe6jckdeORzptbj68GZzbh5tGb_tNRz3PhzEl9AyVycKv0Y941Qo6Ttn8ppC6S0fZesRYl5ShcKjiZOxxFWTXTz94stoYOigM-SXOP_fdA0Pjqmp-IlyqI2yt_k5v93uopp8tzF13TfMwkTrO4lBHbnuMlQTVZFYhzJQEW-keQJP4hQk51nGMhLV_9n_eIvNWzRPiMOP8Ktc6Ul0hEqG7dg5Z-CntUYvz_Akh3U-Sm4nCDOMmgH5O0an0jiuitDokOS7CASpooljLDjFOdhA85O1q_muHeOn7ZYocj5OnQhJC737z1XMApa96UoKq4LDV02cKel9TrVmB3VESvqUQIyFGy0kD2zLOdhR49ugB0bdUn2fnlgKBwudq-5jw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/apellis.com\/our-science\/clinical-trials<\/a>.<\/p>\n<p>\n        <strong>About Apellis<\/strong><br \/>\n        <br \/>Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Entutg6L3FLRlg6BtRzpjQtJHHnqeG9nLuqksFiqejSu_ka0cFIQeOycSC4z4XFtsb8wnCMQscsfw3SMyvihOQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.apellis.com<\/a>.<\/p>\n<p>\n        <strong>About Sobi\u2122<\/strong><br \/>\n        <br \/>Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of hematology, immunology and specialty indications. Today, Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and North Africa. In 2019, Sobi\u2019s revenues amounted to SEK 14.2 billion. Sobi\u2019s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com.<\/p>\n<p>\n        <strong>Apellis Forward-Looking Statement<\/strong><br \/>\n        <br \/>Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements\u201d within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether the company\u2019s clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of results that will be generated in future clinical trials; whether\u00a0pegcetacoplan\u00a0will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company\u2019s clinical trials will warrant regulatory submissions and whether\u00a0pegcetacoplan\u00a0will receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis\u2019 products receive approval, they will be successfully distributed and marketed; and other factors discussed in the \u201cRisk Factors\u201d section of Apellis\u2019 Quarterly Report on Form 10-Q filed with the\u202fSecurities and Exchange Commission\u202fon November 2, 2020\u202fand the risks described in other filings that Apellis may make with the\u202fSecurities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p>For more information please contact<\/p>\n<p>\n        <strong>Apellis<\/strong><br \/>\n        <br \/>Media<br \/>Tracy Vineis<br \/>media@apellis.com<br \/>+1 617 420 4839<\/p>\n<p>\n        <strong>Investor\u202fContact:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>apellis@argotpartners.com<br \/>+1\u202f212.600.1902<\/p>\n<p>\n        <strong>Sobi<\/strong><br \/>\n        <br \/>Paula Treutiger, Head of Communication &amp; Investor Relations<br \/>+ 46 733 666 599<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6_bbEV3MDukoev54ac2por17dhgrz0RRMLcQq1KoccKp-3Y5ky5hh95F0bNB0RVtWILZpO48W8MZR1qv1QlRJLuAy-S0f1ExIfDX1h9MPNM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">paula.treutiger@sobi.com<\/a>\u00a0<\/p>\n<p>Linda Holmstr\u00f6m, Corporate Communication &amp; Investor Relations<br \/>+ 46 708 734\u00a0095<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iFKnitK2zz7fpadSXLXecuYYodrWVz8YOvDG7ir5voGwo-dR6OxAE7C1j5QD3nz1JamdvVhrw12NJcMJqZeOEKcXNrnp3mpgZKBo2EDXBHk=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">linda.holmstrom@sobi.com<\/a><\/p>\n<p>\n        <sup>1 <\/sup>National Institute of Neurological Disorders and Stroke. (2020). Amyotrophic Lateral Sclerosis Fact Sheet. Retrieved from https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Amyotrophic-lateral-Sclerosis-ALS-Fact-Sheet<br \/><sup>2<\/sup> ALS Association. What is ALS? Retrieved June 2020 from https:\/\/www.als.org\/understanding-als\/what-is-als<br \/><sup>3 <\/sup>Bahia El Idrissi N, et al. J Neuroinflammation. 2016;13(1):72.4 Sta M, et al. Neurobiol Dis. 2011;42(3):211-220.<br \/><sup>4 <\/sup>Woodruff, et al., PNAS January 7, 2014 111 (1) E3-E4<br \/><sup>5 <\/sup>Lee, et al Journal of Neuroinflammation volume 15: 171 (2018)25 Arthur K et al. Nat Commun, 2016, Vol 7, article 12408<br \/><sup>6 <\/sup>Arthur K et al. Nat Commun, 2016, Vol 7, article 12408<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ad1cac16-6011-426b-b256-24c4d558679b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi\u2122) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS). Studies suggest that elevated levels of C3 may play a role in the progression of ALS, a neurodegenerative disease that leads to progressive muscle weakness and paralysis. The MERIDIAN study will assess whether pegcetacoplan may offer a new treatment approach for people living with ALS &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384748","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi\u2122) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS). Studies suggest that elevated levels of C3 may play a role in the progression of ALS, a neurodegenerative disease that leads to progressive muscle weakness and paralysis. The MERIDIAN study will assess whether pegcetacoplan may offer a new treatment approach for people living with ALS &hellip; Continue reading &quot;Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T11:48:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan\",\"datePublished\":\"2020-11-19T11:48:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/\"},\"wordCount\":1356,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/\",\"name\":\"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\",\"datePublished\":\"2020-11-19T11:48:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/","og_locale":"en_US","og_type":"article","og_title":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk","og_description":"52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS WALTHAM, Mass. and STOCKHOLM, Sweden, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; \u00a0Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi\u2122) (STO:SOBI) today announced that the first patient has been dosed in the potentially registrational Phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS). Studies suggest that elevated levels of C3 may play a role in the progression of ALS, a neurodegenerative disease that leads to progressive muscle weakness and paralysis. The MERIDIAN study will assess whether pegcetacoplan may offer a new treatment approach for people living with ALS &hellip; Continue reading \"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T11:48:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan","datePublished":"2020-11-19T11:48:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/"},"wordCount":1356,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/","name":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=","datePublished":"2020-11-19T11:48:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODg2NSMzODM0NDkxIzIwMjAwMjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apellis-and-sobi-announce-first-patient-dosed-in-potentially-registrational-als-study-of-pegcetacoplan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384748"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}